Quick Answer
Sonoma Pharmaceuticals, Inc. reported Total Revenue of $14.29 million for fiscal year 2025.
Sonoma Pharmaceuticals, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $14.29M +12.2% |
$12.73M -4.0% |
$13.27M +5.1% |
$12.63M -32.2% |
$18.63M +3.9% |
$17.93M -5.5% |
| Revenue (ASC 606) | — | — | — | — | $18.63M +3.9% |
$17.93M -5.5% |
| Net Income | -$3.46M +28.5% |
-$4.83M +6.1% |
-$5.15M -1.3% |
-$5.09M -28.8% |
-$3.95M -19.4% |
-$3.31M +72.0% |
| Diluted EPS | -$2.79 +73.8% |
-$10.63 -599.3% |
-$1.52 +20.8% |
-$1.92 | — | — |
| Total Assets | $13.69M -7.1% |
$14.74M -9.2% |
$16.23M -13.9% |
$18.84M +25.7% |
$14.99M +2.9% |
$14.56M +0.8% |
| Cash and Equivalents | $5.37M +71.8% |
$3.13M -18.1% |
$3.82M -48.4% |
$7.40M +75.3% |
$4.22M +14.3% |
$3.69M +0.1% |
| Long-Term Debt | — | — | — | $0.00 -100.0% |
$1.31M | $0.00 -100.0% |
| Stockholders Equity | $4.41M -28.1% |
$6.14M -23.1% |
$7.98M -8.3% |
$8.70M +62.2% |
$5.36M -4.6% |
$5.62M -27.6% |
| R&D Expense | $1.81M -3.0% |
$1.87M +803.9% |
$207.0K +65.6% |
$125.0K -77.5% |
$555.0K -58.6% |
$1.34M -11.8% |
| Operating Income | -$3.71M +21.1% |
-$4.70M -2.9% |
-$4.57M +22.4% |
-$5.89M -70.7% |
-$3.45M +53.3% |
-$7.39M +34.4% |
| Gross Profit | $5.46M +15.2% |
$4.75M +6.0% |
$4.48M +12.1% |
$3.99M -39.1% |
$6.56M -19.2% |
$8.12M -8.5% |
| Shares Outstanding | 1.63M +109.4% |
780,371 -84.2% |
4.93M +59.1% |
3.10M +48.2% |
2.09M +17.7% |
1.78M +35.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | December 31, 2025 | $4.35M | +22.0% | -22.4% |
| Revenue (ASC 606) | December 31, 2021 | $2.90M | -41.2% | -22.5% |
| Net Income | December 31, 2025 | -$819.0K | +11.7% | -53.4% |
| Diluted EPS | December 31, 2025 | -$0.48 | +23.8% | -50.0% |
| Total Assets | December 31, 2025 | $13.62M | -0.3% | -1.7% |
| Cash and Equivalents | December 31, 2025 | $2.56M | -51.1% | -15.6% |
| Long-Term Debt | December 31, 2022 | $15.0K | — | +0.0% |
| Stockholders Equity | December 31, 2025 | $3.43M | -29.5% | -9.4% |
| R&D Expense | December 31, 2025 | $557.0K | +30.4% | -3.1% |
| Operating Income | December 31, 2025 | -$678.0K | +34.2% | -101.2% |
| Gross Profit | December 31, 2025 | $1.65M | +29.9% | -22.2% |
| Shares Outstanding | December 31, 2025 | 1.73M | +7.1% | +4.9% |
- Sonoma Pharmaceuticals, Inc. reported Total Revenue of $14.29 million for fiscal year 2025.
- Sonoma Pharmaceuticals, Inc. showed an increase of +12.2% in Total Revenue compared to the prior fiscal year.
- Sonoma Pharmaceuticals, Inc. reported Revenue (ASC 606) of $18.63 million for fiscal year 2021.
- Sonoma Pharmaceuticals, Inc. showed an increase of +3.9% in Revenue (ASC 606) compared to the prior fiscal year.
- Sonoma Pharmaceuticals, Inc. reported Net Income of -$3.46 million for fiscal year 2025.
- Sonoma Pharmaceuticals, Inc. showed an increase of +28.5% in Net Income compared to the prior fiscal year.
- Sonoma Pharmaceuticals, Inc. reported Diluted EPS of $2.79 per share (loss) for fiscal year 2025.
- Sonoma Pharmaceuticals, Inc. showed an increase of +73.8% in Diluted EPS compared to the prior fiscal year.
- Sonoma Pharmaceuticals, Inc. reported Total Assets of $13.69 million for fiscal year 2025.
- Sonoma Pharmaceuticals, Inc. showed a decrease of -7.1% in Total Assets compared to the prior fiscal year.
- Sonoma Pharmaceuticals, Inc. reported Cash and Equivalents of $5.37 million for fiscal year 2025.
- Sonoma Pharmaceuticals, Inc. showed an increase of +71.8% in Cash and Equivalents compared to the prior fiscal year.
- Sonoma Pharmaceuticals, Inc. reported Long-Term Debt of $0.00 for fiscal year 2022.
- Sonoma Pharmaceuticals, Inc. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- Sonoma Pharmaceuticals, Inc. reported Stockholders Equity of $4.41 million for fiscal year 2025.
- Sonoma Pharmaceuticals, Inc. showed a decrease of -28.1% in Stockholders Equity compared to the prior fiscal year.
- Sonoma Pharmaceuticals, Inc. reported R&D Expense of $1.81 million for fiscal year 2025.
- Sonoma Pharmaceuticals, Inc. showed a decrease of -3.0% in R&D Expense compared to the prior fiscal year.
- Sonoma Pharmaceuticals, Inc. reported Operating Income of -$3.71 million for fiscal year 2025.
- Sonoma Pharmaceuticals, Inc. showed an increase of +21.1% in Operating Income compared to the prior fiscal year.
- Sonoma Pharmaceuticals, Inc. reported Gross Profit of $5.46 million for fiscal year 2025.
- Sonoma Pharmaceuticals, Inc. showed an increase of +15.2% in Gross Profit compared to the prior fiscal year.
- Sonoma Pharmaceuticals, Inc. reported Shares Outstanding of 1.63 million shares for fiscal year 2025.
- Sonoma Pharmaceuticals, Inc. showed an increase of +54.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: